Hematopoietic stem cell transplants for multiple myeloma

Leukemia and Lymphoma

Volumn 22, Issue 1-2, 1996, Pages 25-36

  Tricot, Guido ^a,b   Jagannath, Sundar ^a   Vesole, David H ^a   Bracy, Dwayne ^a   Desikan, K R ^a   Siegel, David ^a   Barlogie, Bart ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Division of Hematology   (United States)

Author keywords

Hematopoietic stem cells; Multiple myeloma; Transplant

Indexed keywords

ALPHA INTERFERON; MELPHALAN; PREDNISONE;

AUTOTRANSPLANTATION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CYTOPENIA; HEMATOPOIETIC STEM CELL; HUMAN; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

EID: 0029922810     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199609051725     Document Type: Review

References (79)

1. Barlogie, B., Alexanian, R. and Jagannath, S. (1992) Plasma cell dyscrasias. JAMA, 268, 2946-2951.
2. Barlogie, B., Epstein, J., Selvanayagam, P. and Alexanian, R. (1989) Plasma cell myeloma - New biological insights and advances in therapy. Blood, 73, 865-879.
3. Kyle, R. A. (1983) Long-term survival in multiple myeloma. N. Engl. J. Med., 308, 314-316.
4. Gregory, W. M., Richards, M. A. and Malpas, J. S. (1992) Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: An overview of published trials. J. Clin. Oncol., 10, 334-342.
5. 2 microglobulin in myeloma: A Southwest Oncology Group study. Blood. 75, 823-830.
6. Bataille, R., Boccadoro, M., Klein, B., Durie, B. and Pileri, A. (1992) C-reactive protein and β-2 microglobulin produce a simple and powerful myeloma staging system. Blood, 80, 733-737.
7. 2-microglobulin predict survival independent of thymidine kinase and c-reactive protein in multiple myeloma. Blood, 81, 3382-3387.
8. San Miguel, J. F., Garcia-Sanz. R., Gonzalez, M., Moro, M. J., Hernandez, J. M., Ortega, F., Borrego, D., Carnero, M., Casanova, F., Jimenez, R., Portero and J. A., Orfao, A. (1995) A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood, 85, 448-455.
9. Ffrench, M.. Ffrench, P., Remy, F., Chapuis-Cellier, C., Wolowiec, D., Ville, D. and Bryon, P. A. (1995) Plasma cell proliferation in monoclonal gammopathy: Relations with other biologic variables - diagnostic and prognostic significance. Am. J. Med., 98, 60-66.
10. Dewald, G. W., Kyle, R. A., Hicks, G. A. and Greipp, P. R. (1985) The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, oramyloidosis. Blood, 66, 380-390.
11. Lai, J. L., Zandecki. M., Mary, J. Y., Bernardi, F.. Izydorczyk, V., Flactif, M., Moret, P., Jouet, J. P., Bauters, F. and Facon, T. (1995) Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis. Blood. 85, 2490-2497.
12. Dimopoulos, M. A., Barlogie, B., Smith, T. L. and Alexanian, R. (1991) High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann. Intern. Med., 115, 931-935.
13. Greipp. P. R., Raymond N. M., Kyle, R. A. and O'Fallon, W. M. (1985) Multiple myeloma: Significance of plasmablastic subtype in morphological classification. Blood, 65, 305-310.
14. Salmon, S. E., Tesh, D., Crowley, J., Saeed, S., Finley, P., Milder, M. S., Hutchins, L. F., Coltman, C. A., Bonnet, J. D., Cheson, B., Knost, J. A., Samhouri, A., Beckord, J. and Stock-Novack, D. (1990) Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: A Southwest Oncology Group study. J. Clin. Oncol., 8, 1575-1584.
15. Cooper, M. R., Dear, K., McIntyre, O. R., Ozer, H., Ellerton, J., Canellos, G., Bernhardt, B., Duggan, D., Faragher, D. and Schiffer, C. (1993) A randomized clinical trial comparing melphalan/prednisolone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: A cancer and leukemia group B study. J. Clin. Oncol. 11, 155-160.
16. Blade, J., Lopez-Guillermo, A., Bosch, F., Cervantes, F., Reverter, J-C., Montserrat, E. and Rozman, C. (1994) Impact of response to treatment on survival in multiple myeloma: Results in a series of 243 patients. Br. J. Haematol., 88, 117-121.
17. MacLennan, I. C. M., Chapman, C., Dunn, J. and Kelly, K. (1992) Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet, 339, 200-205.
18. Osterborg, A., Bjorkholm, M., Bjoreman, M., Brenning, F., rlson, K., Celsing, F., Gahrton, G., Grimfors, G., Gyllenhammar, Hast, R., Johansson, B., Juliusson, G., Jarnmark, M., Kimby, E., Lerner, R., Linder, O., Merk, K., Nilsson, B., Ohrling, M., Paul, C., Simonsson, B., Smedmyr, B., Svedmyr, E., Stalfelt, A-M., Strander, H., Uden, A-M., Osby, E. and Mellstedt, H. (1993) Natural interferon-a in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: A randomized study from the Myeloma Group of Central Sweden. Blood, 81, 1428-1434.
19. Boccadoro, M., Marmont, F., Tribalto, M., Avvisati, G., Andriani, A., Barbui, T., Cantonetti, M., Carotenuto, M., Camotti, B., Dammacco, F., Frieri, R., Gallamini, A., Gallone, G., Giovangrossi, P., Grignani, F., Lauta, V. M., Liberati, M., Musto, P., Neretto, G., Petrucci, M. T.. Resegotti, L., Pileri, A. and Mandelli, F. (1991) Multiple myeloma: VMCP/ AP alternating combination chemotherapy is not superior t elphalan and prednisone even in high-risk patients. J. Clin. Onc 9, 444-448.
20. Alexanian, R., Barlogie and B., ucker, S. (1990) VAD-based regimens as primary treatment for multiple myeloma. Am. J. Hematol., 33, 86-89.
21. Alexanian, R., Dimopoulos, M. A., Delasalle, K. and Barlogie, B. (1992) Primary dexamethasone treatment of multiple myeloma. Blood, 80, 887-890.
22. Hata, H., Xiao, H., Petrucci, M. T., Woodliff, J., Chang, R. and Epstein, J. (1993) Interleukin-6 gene expression in multiple myeloma: A characteristic of immature tumor cells. Blood, 81, 3357-3364.
23. Epstein, J., Xiao, H. and Oba, B. K. (1989) P-Glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood, 74, 913-917.
24. McElwain, T. J. and Powles, R.L. (1983) High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet, 822-824.
25. Vesole, D. H., Barlogie, B., Jagannath, S., Cheson, B., Tricot, G., Alexanian, R. and Crowley, J. (1994) High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood, 84, 950-956.
26. Selby, P., McElwain, T., Mana, A. and Nandi, A. C. (1987) Multiple myeloma treated with high-dose intravenous melphalan. Br. J. Haematol., 66, 55-62.
27. Cunningham, D., Paz-Ares, L.,Gore, M. E., Malpas, J., Hickish, T., Nicolson, M., Meldrum, M., Viner, C., Milan, S., Selby, P. J., Normal, A., Raymond, J. and Powles, R. (1994) High-dose melphalan for multiple myeloma: long-term follow-up data. J. Clin. Oncol., 12, 764-768.
28. Lokhorst, H. M., Meuwissen, O. J. A. T., Verdonck, L. F. and Dekker, A. W. (1992) High-risk multiple myeloma treated with high-dose melphalan. J. Clin. Oncol., 10, 47-51.
29. Cunningham, D., Paz-Ares, L., Milan, S., Powles, R., Nicolson, M., Hickish, T., Selby, P., Treleavan. J., Viner, C., Malpas, J., Slevin, M., Findlay, M., Raymond, J. and Gore, M. E. (1994) High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J. Clin. Oncol., 12, 759-763.
30. Harousseau, J-L., Attal, M., Divine, M., Marit, G., Leblond, V., Stoppa, A-M., Bourhis J-H., Caillot, D., Boasson, M., Abgrall, J-F., Facon, T., Linassier, C., Cahn, J-Y., Lamy, T., Troussard, X., Gratecos, N., Pignon, B., Auzanneau, G. and Bataille, R. (1995) Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the French Registry on autologous transplantation in multiple myeloma. Blood, 85, 3077-3085.
31. Barlogie, B., Jagannath, S., Vesole, D., Miller, L., Cheson, B., Bracy, D. and Tricot, G. (1994) Total therapy (TT) for 202 newly diagnosed patients (PTS) with multiple myeloma (MM). Blood, 84(Suppl 1):386a, (abstr).
32. Speed, D. E., Galton, D. A. G. and Swan, A. (1964) Melphalan in the treatment of myelomatosis. Br. Med. J., 1, 1964-1969.
33. Zucchetti, M., D'lncalci, M., Willems, Y., Cavalli, F. and Serra, C. (1988) Lack of effect of cisplatinon IV L-PAM plasma pharmacokinetics in ovarian cancer patients. Cancer Chemother. Pharmacol., 22, 87-89.
34. Osterborg, A., Ehrsson, H., Eksborg, S., Wallin, I. and Mellistedt, H. (1989) Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients. Eur. J. Cancer Clin. Oncol., 25, 899-903.
35. Harousseau, J. L., Milpied, N., Laporte, J. P., Collombat, P., Facon, T., Tigaud, J. D., Casassus, P., Guilhot, F., Ifrah, N. and Gandhour, C. (1992) Double-intensive therapy in high-risk multiple myeloma. Blood, 79, 2827-2833.
36. Tricot, G., Alberts, D. S., Barlogie, B., Dorr, R. T., Vesole, D. H., Jagannath, S., Meyers, R. and Roe, D. High-dose melphalan pharmacokinetics in multiple myeloma, (submitted).
37. Tricot, G., Sawyer, J., Jagannath, S., Bracy, D., Mattox, S., Vesole, D., Naucke, S. and Barlogie, B. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11 q and not with other karyotype abnormalities. Blood, (in press).
38. Tricot, G., Jagannath, S., Vesole, D., Nelson, J., Tindle, S., Miller, L., Cheson, B., Crowley, J. and Barlogie, B. (1995) Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood, 85, 588-596.
39. Tricot, G., Jagannath, S., Vesole, D., Crowley, J. and Barlogie, B. Relapse of multiple myeloma after autologous transplantation: Survival after salvage therapy. Bone Marrow Transplant, (in press).
40. Bell, J. B. G., Maitland, J. A., Gore, M., Millar, B. C. et al (1988) Increase in clonogenic tumour cells in bone marrow of patients with multiple myeloma treated with vincristine, doxorubicin, and methyl-prednisolone. Lancet, 2, 931-933.
41. Abdou, N. I. and Abdou, N. L. (1975) The monoclonal nature of lymphocytes in multiple myeloma. Ann. Intern. Med., 83, 42-45.
42. Mellstedt, H., Hammarstrom, S. and Holm, G. (1974) Monoclonal lymphocyte population in human plasma cell myeloma. Clin. Exp. Immunol., 17, 371-384.
43. Bast, E., Van Camp, B., Reynaert, P., Wiringa, G. et al. (1982) Idiotypic peripheral blood lymphocytes in human monoclonal gammopathy. Clin. Exp. Immunol., 47, 677-682.
44. Carmagnola, A., Boccadoro, M., Massaia, M. and Pileri, A. (1983) The idiotypic specificities of lymphocytes in human monoclonal gammopathies: Analysis with the fluorescence activated cell sorter. Clin. Exp. Immunol., 51, 173-177.
45. Berenson, J., Wong, R., Kim, K., Brown, N. et al (1987) Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood, 70, 1550-1553.
46. Vora, A. J., Toh, C. H., Peel, J. and Greaves, M. (1994) Use of granulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: Risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration. Br. J. Haematol., 86, 180-182.
47. Witzig, T. E., Gertz, M. A., Pineda, A. A., Kyle, R. A. and Greipp, P. R. (1995) Detection of monoclonal plasma cells in the peripheral blood stem cell harvests of patients with multiple myeloma. Br. J. Haematol., 89, 640-642.
48. Bird, J. M., Bloxham, D., Russell, N. H., Samson, D. and Apperley, J. F. (1993) Detection of clonally rearranged cells in PBSC harvests in multiple myeloma by immunoglobulin gene fingerprinting. Blood. 82(Suppl 1). 265a.
49. Dreyfus, F., Ribrag, V., Leblond, V., Ravaud, P., Melle, J., Quarre, M. C., Pillier, C., Boccaccio, C. and Varet, B. (1995) Detection of malignant B cells in peripheral blood stem cell collections after chemotherapy in patients with multiple myeloma. Bone Marrow Transplant., 15, 707-711.
50. Belch, A. R., Bergsagel, P. L., Szczepek, A., Lansdorp, P. and Pilarski. L. M. (1994) CD34+ B cells in the blood of patients with multiple myeloma express clonotypic IgH sequences. Blood, 84(Suppl I), 385a.
51. Vescio, R. A., Hong, C. H., Cao, J., Kim, A., Schiller, G. J., Lichtenstein, A. K., Berenson, R. J. and Berenson, J. R. (1994) The hematopoietic stem cell antigen CD34, is not expressed on the malignant cells in multiple myeloma. Blood, 84, 3283-3290.
52. Gazitt, Y., Reading, C. C., Hoffman, R., Wickrema, A., Vesole, D., Jagannath, S., Condino, J., Lee, B., Barlogie, B. and Tricot, G. (1995) Purified CD34+Lin-Thy+ stem cells do not contain clonal myeloma cells. Blood, 86, 381-389.
53. Anderson, K. C., Barut, B. A., Ritz, J., Freedman, A. S., Takvorian, T., Rabinowe, S. N., Soiffer, R., Heflin, L., Coral, F., Dear, K., Mauch, P. and Nadler, L. M. (1991) Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood, 77, 712-720.
54. Reece, D. E., Barnett, M. J., Connors, J. M., Klingemann, H-G., O'Reilly, S. E., Shepherd, J. D., Sutherland, H. J. and Phillips, G. L. (1993) Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. Bone Marrow Transplant, 11, 139-146.
55. Schiller, G., Vescio, R., Freytes, C., Spitzer, G., Sahebi, F., Lee, M., Wu, C. H., Cao, J., Lee, J. C., Hong, C. H., Lichtenstein, A., Lill, M., Hall, J., Berenson, R. and Berenson, J. (1995) Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood, 86, 390-397.
56. Takishita, M., Kosaka, M., Goto, T. and Saito, S. (1994) Cellular origin and extent of clonal involvement in multiple myeloma: Genetic and phenotypic studies. Br. J. Haematol., 87, 735-742.
57. Bergsagel, P. L., Belch, A. R. and Pilarski, L. M. (1994) The blood B cells and bone marrow plasma cells in a patient with multiple myeloma include cells with the same N-ras mutation. Blood, 84(Suppl I), 524a.
58. Murray, L., Chen, B., Galy, A., Chen, S.,Tushinski, R., Uchida, N., Negrin, R., Tricot, G., Jagannath, S., Vesole, D., Barlogie, B., Hoffman, R. and Tsukamoto, A. (1995) Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin- subpopulation from mobilized peripheral blood. Blood, 85, 368-378.
59. Gazitt, Y., Tian, E., Barlogie, B., Reading, C. C., Vesole, D., Jagannath, S., Schnell, J., Hoffman, R. and Tricot, G. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma following treatment with cyclophosphamide and GM-CSF (submitted).
60. Attal, M., Stoppa, A. M., Sotto, J. J., Fuzibet, G., Rossi, J. F., Casassus, P., Thyss, A., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. and Bataille, R. (1994) High dose therapy in multiple myeloma: A prospective randomized study of the "Intergroupe Francais du Myelome" (IFM). Blood, 84(Suppl I), 386a.
61. Alexanian, R., Dimopoulos, M. A., Hester, J., Delasalle, K. and Champlin, R. (1994) Early myeloablative therapy for multiple myeloma. Blood, 84, 4278-4282.
62. Alexanian, R., Dimopoulos, M., Smith, T., Delasalle, K., Barlogie, B. and Champlin, R. (1994) Limited value of myeloablative therapy for late multiple myeloma. Blood, 83, 512-516.
63. Mandelli, F., Avvisati, G., Amadori, S., Boccadoro, M., Gernone, A., Lauta, V. M., Marmont, F., Petrucci, M. T., Tribalto, M., Vegna, M. L., Dammacco, F. and Pileri, A. (1990) Maintenance treatment with recombinant Interferon Alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N. Engl. J. Med., 322, 1430-1434.
64. Cunningham, D., Powles, R., Malpas, J. S., Milan, S., Meldrum, M., Viner, C, Montes, A., Hickaish, T., Nicolson, M., Johnson, P., Mansi, J., Treleaven, J., Raymond, J. and Gore, M. E. (1993) A randomised trial of maintenance therapy with intron-A following high dose melphalan and ABMT in myeloma. Proc. ASCO, 12, 1232.
65. Miller, J. S., Arthur, D. C., Lite, C. E., Neglia, J. P., Miller, W. J. and Weisdorf, D. J. (1994) Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy. Blood, 83, 3780-3786.
66. Traweek, S. T., Slovak, M. L., Nademanee, A. P., Brynes, R. K., Niland, J. C. and Forman, S. J. (1994) Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood, 84, 957-963.
67. Darrington, D. L., Vose, J. M., Anderson, J. R., Bierman, P. J., Bishop, M. R., Chan, W. C., Morris, M. E., Reed, E. C., Sanger, W. G., Tarantolo, S. R., Weisenburger, D. D., Kessinger, A. and Armitage, J. O. (1994) Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J. Clin. Oncol., 12, 2527-2534.
68. Stone, R. M., Neuberg, D., Soiffer, R., Takvorian, T., Whelan, M., Rabinowe, S. N., Aster J. C., Leavitt, P., Mauch, P., Freedman, A. S. and Nadler, L. M. (1994) Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J. Clin. Oncol., 12, 2535-2542.
69. Pedersen-Bjergaard, J., Ersboll, J., Sorensen, H. M., Keiding, N., Larsen, S. O., Philip, P., Larsen, M. S., Schulte, H. and Nissen, N. I. (1985) Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Ann. Int. Med., 103, 195-200.
70. Levine, E. G. and Bloomfield, C. D. (1992) Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Sem. Oncol., 19, 47-84.
71. Sharp, J. G., Joshi, S. S., Armitage, J. O., Bierman, P., Coccia, P. F., Harrington, D. S., Kessinger, A., Crouse, D. A., Mann, S. L. and Weisenburger, D. D. (1992) Significance of detection of occult non-Hodgkin's lymphoma in histologically univolved bone marrow by a culture technique. Blood, 79, 1074-1080.
72. Brenner, M. K., Rill, D. R., Moen, R. C., Krance, R. A., Mirro, J., Anderson, W. F. and Ihle, J. N. (1993) Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet, 341, 85-86.
73. Meloni, G., Foa, R., Vignetti, M., Guarini, A., Fenu, S., Tosti, S., Tos, A. G. and Mandelli, F. (1994) Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood, 84, 2158-2163.
74. Hoover, R. G., Lary, C., Page, R. and et al. Autoregulatory circuits in myeloma: Tumor cell cytotoxicity mediated by soluble CD16. J. Clin. Invest., (in press).
75. Stevenson, F. K., Bell, A. J., Cusack, R., Hamblin, T. J., Slade, C. J., Spellerberg, M. B. and Stevenson, G. T. (1991) Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood, 77, 1071-1079.
76. Grossbard, M. L., Gribben, J. G., Freedman, A. S., Lambert, J. M., Kinsella, J., Rabinowe, S. N., Eliseo, L., Taylor, J. A., Blattler, W. A., Epstein, C. L. and Nadler, L. M. (1993) Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood, 81, 2263-2271.
77. Calabretta, B. (1991) Inhibition of protooncogene expression by antisense oligodeoxynucleotides: Biological and therapeutic implications. Cancer Res., 51, 4505-4510.
78. Cuthbert, J. A. and Lipsky, P. E. (1995) Suppression of the proliferation of Ras-transformed cells by fluoromevalonate, an inhibitor of mevalonate metabolism. Cancer Res., 55, 1732-1740.
79. Mizutani, Y., Bonavida, B., Koishihara, Y., Akamatsu, K., Ohsugi, Y. and Yoshida O. (1995) Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-Interleukin 6 monoclonal antibody or anti-Interleukin 6 receptor monoclonal antibody. Cancer Res., 55, 590-596.